| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | rBPI; BPIFD1; CAP 57; BPI; Bactericidal permeability-increasing protein;;BPI |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human BPI |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于BPI抗体的代表性文献摘要简述(文献信息为模拟示例)：
1. **《Anti-BPI antibodies in cystic fibrosis: A meta-analysis》**
- 作者：Smith A, et al.
- 摘要：通过荟萃分析探讨囊性纤维化(CF)患者中抗BPI抗体的临床意义，发现其与肺部感染加重及预后不良显著相关，提示可作为疾病活动性生物标志物。
2. **《The role of BPI autoantibodies in autoimmune vasculitis》**
- 作者：Zhang L, et al.
- 摘要：研究抗中性粒细胞胞浆抗体(ANCA)相关性血管炎患者中抗BPI抗体的阳性率及其与肾脏损伤的关联，揭示其可能通过增强中性粒细胞活化加剧组织炎症。
3. **《BPI as a novel target in inflammatory bowel disease》**
- 作者：Johnson R, et al.
- 摘要：首次报道克罗恩病患者血清中抗BPI抗体的存在，并证明其与肠道屏障功能受损相关，为靶向BPI的免疫治疗提供理论依据。
注：以上文献名为虚拟示例，实际研究中可参考以下方向检索：
- 关键词：BPI antibody, anti-BPI autoantibody, bactericidal/permeability-increasing protein, ANCA-negative vasculitis, cystic fibrosis
- 数据库：PubMed/Google Scholar(可筛选近5年高引文献)
**Background of BPI Antibodies**
Bactericidal/Permeability-Increasing Protein (BPI) is a 55-kDa cationic antimicrobial protein primarily produced by neutrophils and epithelial cells. It plays a critical role in innate immunity by targeting Gram-negative bacteria through two functional domains: the N-terminal domain, which neutralizes endotoxins like lipopolysaccharide (LPS) and exerts bactericidal activity, and the C-terminal domain, facilitating bacterial opsonization and clearance. BPI also modulates inflammatory responses by binding and neutralizing circulating LPS, thereby reducing septic shock risk.
BPI antibodies, including autoantibodies and therapeutic monoclonal antibodies, have garnered significant research interest. Autoantibodies against BPI are associated with chronic inflammatory conditions, such as cystic fibrosis (CF) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. These autoantibodies may impair BPI’s antibacterial function, exacerbating infections or inflammation. In CF, anti-BPI antibodies correlate with poorer lung function and *Pseudomonas aeruginosa* colonization.
Therapeutically, recombinant BPI or BPI-derived peptides have been explored as adjuvants to combat sepsis or antibiotic-resistant infections. Monoclonal antibodies mimicking BPI’s LPS-neutralizing effects are also under investigation. However, challenges remain in balancing efficacy with potential immunogenicity. Overall, BPI antibodies represent a dual focus: understanding their pathogenic role in autoimmune diseases and harnessing their therapeutic potential in infectious and inflammatory disorders.
×
